UCB SA (FRA:UNC)

Market Cap	48.53B +39.7%
Revenue (ttm)	6.85B +25.6%
Net Income	1.33B +455.0%
EPS	6.87 +462.0%
Shares Out	n/a
PE Ratio	36.43
Forward PE	27.81
Dividend	0.97 (0.38%)
Ex-Dividend Date	Apr 25, 2025

Volume	n/a
Average Volume	36
Open	254.00
Previous Close	263.00
Day's Range	254.00 - 254.00
52-Week Range	135.90 - 263.00
Beta	n/a
RSI	51.93
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 8,600
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UNC

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.